Skip to content
Subscriber Only

Biogen Faces Democrats’ Ire Over Price Tag for Alzheimer’s Drug

Bloomberg business news
Biogen CEO Sees New Chapter in Fight Against Alzheimer's

The cost of Biogen Inc.’s new Alzheimer’s drug is drawing criticism from Democratic lawmakers just a day after its approval by U.S. regulators.

The $56,000-a-year price tag for Biogen’s Aduhelm “will likely cost Medicare billions of dollars,” said Carolyn Maloney, chair of the House Oversight Committee, in an emailed statement. Ron Wyden, chair of the Senate Finance Committee, tweeted on Tuesday that it’s “unconscionable” to charge so much for a drug that hasn’t been proven to work.